Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Nihon Kohden partner in haematology:

This article was originally published in Clinica

Executive Summary

Nihon Kohden and Abbott have entered into an agreement to commercialise automated haematology diagnostic instruments manufactured by Nihon Kohden of Tokyo, Japan. The products will be distributed exclusively by Abbott under the CELL-DYN Pearl brand name in the US and Canada. The Abbott Park, Illinois company also has non-exclusive distribution rights in all other markets apart from China and Japan. Harold Flynn, divisional vice-president and general manager of Abbott Hematology, said that the new agreement provided an opportunity to expand Abbott's instrument offering for smaller hospitals, large clinics and physician offices.

You may also be interested in...



Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia

Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.

US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.

Most Pharmacies Ready For COVID-19 Vaccines; Ultra-Cold Storage Still A Limitation

Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel